• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Outcomes not improved with early amoxicillin-clavulanate in cardiac arrest patients

byNiki WintersandDeepti Shroff Karhade
December 2, 2019
in Cardiology, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A 2-day course of amoxicillin-clavulanate and targeted temperature management of 32-34 degrees Celsius after cardiac arrest with shockable rhythm resulted in a lower incidence of early ventilator-associated pneumonia than the control group.

2. The intervention did not cause a significant decrease in the rate of late ventilator-associated pneumonia, number of ventilator-free days, ICU length of stay, and mortality at day 28 as compared to the control group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Survival rates upon discharge among patients with out-of-hospital cardiac arrests is poor, remaining below 20%. In addition, targeted temperature management is recommended in such patients but is associated with increased risk of infection. This randomized controlled trial was designed to test the use of antibiotics plus temperature control to decrease the amount of ventilator-associated pneumonia in patients with out-of-hospital cardiac arrest with a shockable rhythm. A 2-day course of amoxicillin-clavulanate and targeted temperature management of 32-34°C after cardiac arrest with shockable rhythm resulted in a lower incidence of early ventilator-associated pneumonia. A higher frequency of enterobacteria was seen in patients that received amoxicillin-clavulanate. No significant difference was seen between the two groups in the rate of late ventilator-associated pneumonia, number of ventilator-free days, ICU length of stay, and mortality at day 28. Given the small sample size and specific inclusion criteria, further research is required to determine whether antibiotics and targeted temperature control decrease the amount of early ventilator-associated pneumonia in cardiac arrest patients, and if the findings can be applied to other populations.

Click to read the study in NEJM

Relevant Reading: Ventilator Management and Respiratory Care After Cardiac Arrest

In-Depth [randomized controlled trial]: This randomized controlled trial was conducted in France in 16 ICUs from August 2014 to September 2017 to determine the benefit of targeted temperature management plus antibiotics in preventing early ventilator-associated pneumonia for cardiac arrest patients.194 adult patients in the ICU hospitalized for out-of-hospital cardiac arrest with shockable rhythm and treated with 32 to 34°C temperature management were included in this trial. Patients with in-hospital arrests, non-shockable rhythms, ongoing pneumonia, or contraindication to the antibiotics were excluded. Amoxicillin-clavulanate was started within 6 hours after the return of spontaneous circulation and given for 2 days while temperature management was maintained. The incidence of early ventilator-associated pneumonia was lower among patients who received the intervention as compared to the control group (19% vs. 34%; 95% CI 0.31 to 0.92; P=0.03), but the incidence of late ventilator-associated pneumonia was similar between the groups. Overall antibiotic use during the ICU stay tended to be lower for patients in the antibiotic group as compared to the control group (23% vs. 50%). In addition, more gram-negative bacilli cases were seen in the antibiotic group (such as enterobacteria) as compared to the control group. No difference was found in nonpulmonary secondary infections, median number of ventilator-free days, median ICU length of stay, adverse events, and mortality between the two groups.

RELATED REPORTS

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest

Smartphone volunteer app dispatches may increase Automated External Defibrillator use

Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest – the SAMBA trial

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: amoxicillin–clavulanatecardiac arrestpneumoniaventilator associated pneumonia
Previous Post

2 Minute Medicine Rewind December 2, 2019

Next Post

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

RelatedReports

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest

December 21, 2022
Metronome use linked to rate optimization in pediatric CPR
Cardiology

Smartphone volunteer app dispatches may increase Automated External Defibrillator use

December 16, 2022
Bystander and first-responder initiated CPR associated with improved outcomes
Cardiology

Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest – the SAMBA trial

December 10, 2022
#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation
StudyGraphics

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

December 7, 2022
Next Post
#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

Many new pediatric asthma cases attributable to obesity

Risk of major adverse cardiovascular events varies with dynamic metabolic syndrome status

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options